Skip to main content

Advertisement

SpringerLink
Log in

Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib.

Methods

A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated.

Results

According to the cut-off points, patients were divided into two groups. The patients in the high IPI group showed poorer OS compared to patients in the low IPI groups. The PFS was better in patients with low neutrophil-lymphocyte ratio (NLR) and platelet-neutrophil to lymphocyte ratio (PNLR), and the OS was better in patients with low IPI.

Conclusion

Among the immune inflammation scores analyzed in mCRC patients receiving regorafenib, NLR and PNLR were the best predictor of recurrence, whereas IPI was the best predictor of long-term survival. After being confirmed by better designed controlled trials, IPI can be used to identify the group of patients who will benefit more from regorafenib treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.

  3. Diakos CI, Charles KA, McMillan DC. SJ Clarke Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503.

    Article  Google Scholar 

  4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454 (7203): 436e444.

  5. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008;102(6):756–61.

    Article  Google Scholar 

  6. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–72.

    Article  Google Scholar 

  7. Mercier J, Voutsadakis IA. The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. J Gastrointest Oncol. 2018;9(3):478–86.

    Article  Google Scholar 

  8. Dirican N, Dirican A, Anar C, et al. A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases. Asian Pac J Cancer Prev. 2016;17:5101–6.

    PubMed  PubMed Central  Google Scholar 

  9. Ohki S, Shibata M, Gonda K, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep. 2012;28:453–8.

    Article  Google Scholar 

  10. Carreau NA, Diefenbach CS. Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist. Ther Adv Hematol. 2019;10:2040620719846451.

    Article  CAS  Google Scholar 

  11. Pine JK, Morris E, Hutchins GG, West NP, Jayne DG, Quirke P, Prasad KR. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113(2):204–11.

    Article  CAS  Google Scholar 

  12. Quigley DA, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol. 2015;9:2054–62.

    Article  CAS  Google Scholar 

  13. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64:2865–73.

    Article  CAS  Google Scholar 

  14. Yoneyama Y, Ito M, Sugitou M, Kobayashi A, Nishizawa Y, Saito N. Postoperative lymphocyte percentage influences the long-term disease-free survival following a resection for colorectal carcinoma. Jpn J Clin Oncol. 2011;41(3):343e347.

  15. Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, Scartozzi M, Cascinu S. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget. 2015;6(32):33982–92.

    Article  Google Scholar 

  16. Clarke SJ, Burge M, Feeney K, et al. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]. PLoS One. 2020;15(3):e0229900.

    Article  CAS  Google Scholar 

  17. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362–7.

    Article  CAS  Google Scholar 

  18. Sun H, Hu P, Shen H, et al. Albumin and neutrophil combined prognostic grade as a new prognostic factor in non-small cell lung cancer: results from a large consecutive cohort. PLoS One. 2015;10:e0144663.

    Article  Google Scholar 

  19. Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–48.

    Article  CAS  Google Scholar 

  20. Teufel M, Kalmus J, Rutstein MD, et al. Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC) [abstract no. 672]. J Clin Oncol. 2016;34(4 Suppl).

Download references

Acknowledgements

The authors would like to thank Prof. Dr. Gamze Göksel for providing guidance and feedback throughout this research.

Author information

Authors and Affiliations

  1. Medical Faculty Department Of Internal Medicine Divison Of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey

    Atike Pınar Erdoğan, Ferhat Ekinci, Aykut Karabaş, Onur Yazdan Balçık & Sabri Barutça

  2. Department Of Internal Medicine Divison Of Medical Oncology , Izmir Economy University Medical Faculty , İzmir, Turkey

    Ahmet Dirican

Authors
  1. Atike Pınar Erdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferhat Ekinci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aykut Karabaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Onur Yazdan Balçık
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabri Barutça
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Dirican
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atike Pınar Erdoğan.

Ethics declarations

Ethics Approval

Approval was obtained from the Medical Research Ethics Committee of the Manisa Celal Bayar University Faculty of Medicine with the number 80 dated 15.06.2020.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erdoğan, A.P., Ekinci, F., Karabaş, A. et al. Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?. J Gastrointest Canc 53, 45–51 (2022). https://doi.org/10.1007/s12029-021-00642-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00642-w

Keywords

Search

Navigation